Oncternal Therapeutics Inc (NASDAQ:ONCT) — Market Cap & Net Worth
Market Cap & Net Worth: Oncternal Therapeutics Inc (ONCT)
Oncternal Therapeutics Inc (NASDAQ:ONCT) has a market capitalization of $1.56 Million ($1.56 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30185 globally and #6063 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oncternal Therapeutics Inc's stock price $0.53 by its total outstanding shares 2959640 (2.96 Million). Review Oncternal Therapeutics Inc balance sheet liabilities to assess the company's total debt and financial obligations.
Oncternal Therapeutics Inc Market Cap History: 2015 to 2025
Oncternal Therapeutics Inc's market capitalization history from 2015 to 2025. Data shows change from $2.90 Billion to $1.56 Million (-56.22% CAGR).
Oncternal Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oncternal Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
40.72x
Oncternal Therapeutics Inc's market cap is 40.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.19 Billion | $-2.51 Million | -$17.72 Million | -871.27x | N/A |
| 2017 | $5.27 Billion | $1.67 Million | -$30.44 Million | 3145.99x | N/A |
| 2018 | $323.19 Million | $2.52 Million | -$38.42 Million | 128.20x | N/A |
| 2019 | $233.81 Million | $2.42 Million | -$15.91 Million | 96.42x | N/A |
| 2020 | $290.04 Million | $3.38 Million | -$17.21 Million | 85.94x | N/A |
| 2021 | $134.37 Million | $4.32 Million | -$31.30 Million | 31.14x | N/A |
| 2022 | $59.19 Million | $1.49 Million | -$43.39 Million | 39.73x | N/A |
| 2023 | $31.96 Million | $785.00K | -$39.48 Million | 40.72x | N/A |
Competitor Companies of ONCT by Market Capitalization
Companies near Oncternal Therapeutics Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Oncternal Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Oncternal Therapeutics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Oncternal Therapeutics Inc's market cap moved from $2.90 Billion to $ 1.56 Million, with a yearly change of -56.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.56 Million | 0.00% |
| 2024 | $1.56 Million | -95.12% |
| 2023 | $31.96 Million | -46.00% |
| 2022 | $59.19 Million | -55.95% |
| 2021 | $134.37 Million | -53.67% |
| 2020 | $290.04 Million | +24.05% |
| 2019 | $233.81 Million | -27.66% |
| 2018 | $323.19 Million | -93.86% |
| 2017 | $5.27 Billion | +140.72% |
| 2016 | $2.19 Billion | -24.57% |
| 2015 | $2.90 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 28th, 2026 the market cap of Oncternal Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.56 Million USD |
| MoneyControl | $1.56 Million USD |
| MarketWatch | $1.56 Million USD |
| marketcap.company | $1.56 Million USD |
| Reuters | $1.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS… Read more